Chen Yimeng, Gao Chao, Sun Qian, Pan Hong, Huang Pei, Ding Jianqing, Chen Shengdi
Laboratory of Neurodegenerative Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of SciencesShanghai, China.
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, China.
Front Aging Neurosci. 2017 Jul 21;9:232. doi: 10.3389/fnagi.2017.00232. eCollection 2017.
Parkinson's disease (PD) is the second most common neurodegenerative disorder and has profound impacts on the daily lives of patients. However, there is a lack of effective biomarkers for early diagnosis, and the mechanisms of PD pathogenesis remain obscure. microRNAs (miRNAs) are post-transcriptional gene regulators and can be easily detected in plasma, which suggests a promising role as diagnostic markers. Here, we aimed to explore a peripheral biomarker, which not only can be applied for early diagnosis of PD but also has the potential to be a therapeutic target. Through miRNA microarray screening and further validation in plasma from 169 sporadic PD patients, 170 healthy controls, and 60 essential tremor (ET) patients, hsa-miR-4639-5p level was identified to be significantly up-regulated in PD patients. Also, it was able to discriminate between early PD patients (disease duration ≤2 years or Hoehn and Yahr stage 1-2.5) and healthy controls. Furthermore, hsa-miR-4639-5p was shown to negatively regulate DJ-1 (PARK7), a well-known PD-related gene, in the post-transcriptional level. Abnormal up-regulation of hsa-miR-4639-5p caused down-regulation of DJ-1 protein level, leading to severe oxidative stress and neuronal death. In conclusion, hsa-miR-4639-5p has the potential to be a peripheral diagnostic biomarker and therapeutic target for early PD.
帕金森病(PD)是第二常见的神经退行性疾病,对患者的日常生活有深远影响。然而,缺乏用于早期诊断的有效生物标志物,且PD发病机制仍不清楚。微小RNA(miRNA)是转录后基因调节因子,可在血浆中轻松检测到,这表明其作为诊断标志物具有广阔前景。在此,我们旨在探索一种外周生物标志物,它不仅可用于PD的早期诊断,还具有成为治疗靶点的潜力。通过对169例散发性PD患者、170例健康对照者和60例特发性震颤(ET)患者的血浆进行miRNA微阵列筛选及进一步验证,发现hsa-miR-4639-5p水平在PD患者中显著上调。此外,它能够区分早期PD患者(病程≤2年或Hoehn和Yahr分期1-2.5)与健康对照者。此外,hsa-miR-4639-5p在转录后水平对著名的PD相关基因DJ-1(PARK7)起负调节作用。hsa-miR-4639-5p的异常上调导致DJ-1蛋白水平下调,进而导致严重的氧化应激和神经元死亡。总之,hsa-miR-4639-5p有潜力成为早期PD的外周诊断生物标志物和治疗靶点。